GenSight Biologics to Present at Key Medical Conferences in 2024

Paris, France, June 4, 2024 – GenSight Biologics, a biopharma company focused on gene therapies for retinal neurodegenerative diseases, announced its participation at important medical and stakeholder meetings throughout 2024. The company will present three papers on its gene therapy, LUMEVOQ®, for Leber Hereditary Optic Neuropathy (LHON) at the 16th Meeting of the European Neuro-Ophthalmology Society in Rotterdam, from June 3 to 6, 2024.

Among the presentations, Catherine Vignal, MD, will discuss the efficacy and safety of LUMEVOQ® in a real-life setting. Nancy J. Newman, MD, will present a meta-analysis of treatment outcomes for LHON patients. Valerio Carelli will share ocular post-mortem analyses following AAV2 gene therapy.

GenSight Biologics will also present at the 2024 Annual Meeting of the American Academy of Ophthalmology and the 27th Annual Congress of the European Association for Vision and Eye Research. On June 5, Chief Medical Officer Magali Taiel will speak at the 2nd Multi-Stakeholders Meeting on Clinical Trials for Inherited Retinal Diseases and the 2024 Mitochondrial Disease Conference in October.